Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0076571
Title: Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine
Authors: Skibinski D.A.G.
Hanson B.J. 
Lin Y.
von Messling V.
Jegerlehner A.
Tee J.B.S.
Chye D.H.
Wong S.K.K.
Ng A.A.P.
Lee H.Y.
Au B.
Lee B.T.K.
Santoso L.
Poidinger M. 
Fairhurst A.-M.
Matter A. 
Bachmann M.F.
Saudan P.
Connolly J.E.
Keywords: adjuvant
aluminum potassium sulfate
gamma interferon
hemagglutinin
immunoglobulin G2a antibody
influenza vaccine
neutralizing antibody
2009 H1N1 influenza
animal experiment
animal model
animal tissue
antibody production
antibody titer
antigen specificity
article
bacteriophage
cellular immunity
covalent bond
cross linking
cytokine production
drug formulation
Escherichia coli
immunization
immunomodulation
mouse
nonhuman
protein domain
spleen cell
Th1 cell
virus like agent
virus load
Adjuvants, Immunologic
Alum Compounds
Animals
Antibodies, Neutralizing
Antibodies, Viral
Antibody Specificity
Bacteriophages
Escherichia coli
Female
Ferrets
Hemagglutinin Glycoproteins, Influenza Virus
Humans
Immunoglobulin G
Influenza A Virus, H1N1 Subtype
Influenza Vaccines
Interferon-gamma
Mice
Orthomyxoviridae Infections
RNA, Bacterial
T-Cell Antigen Receptor Specificity
T-Lymphocyte Subsets
Th1 Cells
Vaccines, Virus-Like Particle
Issue Date: 2013
Citation: Skibinski D.A.G., Hanson B.J., Lin Y., von Messling V., Jegerlehner A., Tee J.B.S., Chye D.H., Wong S.K.K., Ng A.A.P., Lee H.Y., Au B., Lee B.T.K., Santoso L., Poidinger M., Fairhurst A.-M., Matter A., Bachmann M.F., Saudan P., Connolly J.E. (2013). Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine. PLoS ONE 8 (10) : e76571. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0076571
Abstract: Influenza pandemics can spread quickly and cost millions of lives; the 2009 H1N1 pandemic highlighted the shortfall in the current vaccine strategy and the need for an improved global response in terms of shortening the time required to manufacture the vaccine and increasing production capacity. Here we describe the pre-clinical assessment of a novel 2009 H1N1 pandemic influenza vaccine based on the E. coli-produced HA globular head domain covalently linked to virus-like particles derived from the bacteriophage Qβ. When formulated with alum adjuvant and used to immunize mice, dose finding studies found that a 10 μg dose of this vaccine (3.7 μg globular HA content) induced antibody titers comparable to a 1.5 μg dose (0.7 μg globular HA content) of the licensed 2009 H1N1 pandemic vaccine Panvax, and significantly reduced viral titers in the lung following challenge with 2009 H1N1 pandemic influenza A/California/07/2009 virus. While Panvax failed to induce marked T cell responses, the novel vaccine stimulated substantial antigen-specific interferon-γ production in splenocytes from immunized mice, alongside enhanced IgG2a antibody production. In ferrets the vaccine elicited neutralizing antibodies, and following challenge with influenza A/California/07/2009 virus reduced morbidity and lowered viral titers in nasal lavages. © 2013 Skibinski et al.
Source Title: PLoS ONE
URI: https://scholarbank.nus.edu.sg/handle/10635/161461
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0076571
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0076571.pdf1.27 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

12
checked on Oct 23, 2020

Page view(s)

104
checked on Oct 16, 2020

Download(s)

2
checked on Oct 16, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.